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Abstract 
 
Simvastatin (SIM), also known as a HMG-CoA reductase inhibitor, is among the 
most prescribed pharmaceuticals for cardiovascular disease preventions worldwide. It has 
been continuously discharged to aquatic ecosystems, making SIM a compound of emerg-
ing concern. Despite the ubiquitous nature of SIM, its potential effects in aquatic non-
target organisms are not yet fully understood. Several studies have shown that exposure 
to SIM, on µg/L range, is able to produce several adverse effects on aquatic organisms, 
but there is a lack of chronic studies with SIM environmental significant concentrations 
where aquatic organisms are continuously exposed through their life-cycle. 
 The aim of this study was to investigate a multi-level biological response on the 
freshwater teleost fish Danio rerio following a chronic exposure (90 days) to SIM concen-
trations ranging from 12.8 ng/L to 1600 ng/L. We integrated ecological endpoints, i.e. sur-
vival, growth, reproduction, and embryonic development, with biochemical markers of lipid 
content (cholesterol and triglycerides) as well as molecular analysis of transcript levels of 
key genes involved in the mevalonate pathway (hmgcra, cyp51, dhcr7, and srebp2). 
 Most of our results exhibited a non-monotonic dose-response curve with significant 
decrease in cholesterol and mRNA transcript levels of hmgcra, cyp51 and at some extent 
dhcr7, after zebrafish exposure to 64ng/L and 320 ng/L of SIM, followed by an increase to 
near control levels for 1600 ng/L. The same type of response was observed for anomalies 
in the embryonic development. Anomalies increased for concentrations of 12.8 ng/L ad 
64 ng/L of SIM parental exposure, with a decrease in the incidence of anomalies in the 
higher concentrations tested. The highest tested concentration, 1600 ng/L, also induced 
significant alterations at reproductive level, as well as reduced male weight. In addition, 
our experiment revealed opposite results from those in the literature regarding mRNA 
transcript levels of hmgcra and srebp2, which may be due to a longer time of exposure in 
comparison to previous studies.  
These findings have important implications for environmental risk assessment giv-
en that aquatic organisms are chronically exposed to SIM levels in the range of those 
tested here during several generations.   
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Resumo 
 
Sinvastatina (SIM), também conhecida como inibidora da HMG-CoA redutase, es-
tá entre os produtos farmacêuticos mais prescritos para prevenção de doenças cardio-
vasculares em todo o mundo. Quantidades crescentes de SIM são detetadas em ecossis-
temas aquáticos, tornando-se deste modo um composto de preocupação emergente. 
Apesar de a SIM ter uma natureza ubíqua, os seus potenciais efeitos em organismos 
não-alvo aquáticos não são ainda totalmente conhecidos. Vários estudos demostraram 
que a exposição a SIM, a concentrações entre os ng e μg / L, é capaz de produzir vários 
efeitos adversos em organismos aquáticos, no entanto há falta de estudos de exposição 
crónica com concentrações ambientalmente relevantes onde os organismos aquáticos 
são expostos continuamente a SIM ao longo dos seus ciclos de vida. 
O objetivo deste estudo foi investigar respostas biológicas no peixe teleósteo de 
água doce, Danio rerio após uma exposição crónica de 90 dias a concentrações de SIM 
que variaram entre 12.8 ng/L e 1600 ng/L. Integramos parâmetros ecológicos tais como 
sobrevivência, crescimento, reprodução e desenvolvimento embrionário, com marcadores 
bioquímicos (colesterol e triglicerídeos), bem como análises moleculares da expressão de 
genes chave envolvidos na via do mevalonato (hmgcra, cyp51, dhcr7 e srebp2). 
Uma grande parte dos nossos resultados exibiram uma curva de resposta não-
monotónica com uma diminuição significativa dos níveis de colesterol, assim como da 
expressão dos genes hmgcra e cyp51 após exposição a 64 ng/L e 320ng/L de SIM, se-
guida por um aumento para níveis semelhantes ao controlo na concentração mais alta 
(1600 ng/L). O mesmo tipo de curva foi observado para as anomalias formadas durante o 
desenvolvimento embrionário. Observou-se um aumento do número de anomalias para 
embriões em que a geração parental foi exposta a concentrações de SIM de 12.8 ng/L e 
64 ng/L de SIM, seguida de uma diminuição da frequência de anomalias em concentra-
ções superiores. Também foi possível observar alterações a nível reprodutivo e da massa 
corporal em machos na maior concentração testada, 1600 ng/L. O presente estudo reve-
lou resultados opostos à literatura no que diz respeito à expressão génica de hmgcra e 
srebp2, que poderão ser explicados com base numa exposição mais prolongada, em 
comparação com estudos prévios. 
Estes resultados têm importantes implicações para a avaliação do risco ambiental, 
uma vez que os organismos aquáticos se encontram expostos a SIM na natureza duran-
tes várias gerações. 
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1.1. Environmental impact of pharmaceuticals  
1.1.1. Influence of pharmaceuticals’ consumption and market growth in the 
environmental health. 
 
For the last decades, due to the improvement of medical and pharmaceutical sci-
ences, there has been an increase in the life expectancy. Consequently, the percentage 
of population requiring health care has raised, mainly related to growth of chronic diseas-
es such as obesity, diabetes, cardio-pulmonary dysfunctions, etc., (Arnold et al., 2014; 
BIO Intelligence Service, 2013; LaLone et al., 2014). In this context, pharmaceuticals have 
been used in large quantities for the prevention, diagnosis and treatment of such diseases 
(Azzouz & Ballesteros, 2012).  
Since 1990, the EU pharmaceutical market has grown from 48 billion to approxi-
mately 242 billion euros in 2014. EU consumption of pharmaceuticals reached 24% of the 
world’ total, making Europe the second biggest consumer, right after the USA. Several 
studies, performed between 2006 and 2009, revealed that the anti-hypertensors together 
with the analgesics were the most consumed human pharmaceuticals in Europe (500 
Standard Units/capita/year), followed by psychoactives (300 SU/capita/year), anti-
cholesterol or diabetes drugs (150 SU/capita/year), and antibiotics (80 SU/capita/year) 
(BIO Intelligence Service, 2013). 
 In the past, pharmaceuticals were overlooked as pollutants because exposure 
levels were assumed to be reduced to produce significant effects in non-target organisms 
(Arnold et al., 2014; Daughton, 2016; EEA, 1999). However, from mid-1990s, a growing 
attention has been placed in this class of contaminants. Indeed, the detection of pharma-
ceuticals in the environment has increased in the last years, not only because of the 
growth of pharmaceutical industry, but also due to the improvement in the sensibility of the 
chemical quantification analytical methods (LaLone et al., 2014). Most of the pharmaceu-
ticals are detected in the environment at trace levels, generally, concentrations range be-
tween ng/L to low µg/L (Arnold et al., 2014; Azzouz & Ballesteros, 2012; BIO Intelligence 
Service, 2013; Daughton, 2016; Fent et al., 2006). However, since they are bioactive sub-
stances, designed to produce biological effects at rather low concentrations, the scientific 
community is now in broad agreement that pharmaceuticals may pose a considerable en-
vironmental risk (BIO Intelligence Service, 2013). In fact, nowadays, these compounds are 
considered emergent pollutants of concern capable to produce effects at environmentally 
relevant concentrations in non-target organisms (Arnold et al., 2014; Fent et al., 2006). 
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1.1.2. Environmental contamination process  
 
There are several ways by which pharmaceuticals can enter into the environment 
during their life-cycle (Figure 1). Pharmaceutical manufacturing, consumption and waste 
management are considered the main routes of environmental contamination and the wa-
ter bodies are especially vulnerable to emissions of this class of contaminants (Arnold et 
al., 2014; Fent et al., 2006). Pharmaceuticals manufacturing phase at industrial facilities is 
very controlled with generally low emissions that are considered negligible. However, de-
veloping countries have shown to emit significant amounts of pharmaceuticals and their 
active substances to the environment during this phase (Arnold et al., 2014; BIO 
Intelligence Service, 2013; Larsson, 2014; Ortiz de García et al., 2013). The main problem 
lies on the extent of drugs consumption and waste management. Although most EU 
member states have provided collecting systems for unused pharmaceuticals, a substan-
tial amount of these products are discharged through sinks and toilets or as domestic 
waste, due to lack of public awareness about environmental problems around this issue. 
As a result, an average of 50% of the unused medical products are not collected contrib-
uting to the occurrence of pharmaceuticals in sewage systems (Azzouz & Ballesteros, 
2012; BIO Intelligence Service, 2013; EEA, 2010; Fent et al., 2006). On the other hand, 
pharmaceuticals cannot be entirely used by organisms and are released into the sewage 
systems by excretion as mixtures of both native form and active metabolites resulted of its 
biotransformation (BIO Intelligence Service, 2013; Ebele et al., 2017; EEA, 2010; Fent et 
al., 2006).  
 
 
 
Figure 1. Life-cycle steps of pharmaceutical products 
 
These biologically active compounds reach the sewage systems and are then 
treated in sewage treatment plants (STP) and/or wastewater treatment plants (WWTP) 
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(EEA, 2010; Fent et al., 2006). Once in the WWTP, these compounds can be partially re-
moved. However, there is no treatment in these facilities that ensures complete removal of 
all pharmaceuticals, meaning that low but possibly significant amounts of pharmaceutical 
active substances are being discharged into surface waters. For this reason effluents from 
WWTPs are considered one of the most important sources of pharmaceuticals in the 
aquatic environments (Ebele et al., 2017; Fent et al., 2006; Lapworth et al., 2012). Other 
pathways for the entrance of pharmaceuticals in the aquatic environment are the sludge 
spills, the sorption of pharmaceuticals into the activated sludge used as soil fertilizer and 
veterinary medicines that enter directly or indirectly into the water (Figure 2) (Benotti et al., 
2009; BIO Intelligence Service, 2013; Fent et al., 2006; Lapworth et al., 2012). 
 
 
Figure 2. Schematic diagram of sources and pathways of pharmaceuticals in aquatic 
environment. Adapted from Arnold et al., 2014; BIO Intelligence Service, 2013; Ebele et 
al., 2017; Lapworth et al., 2012. 
 
1.1.3. Ecotoxicological effects 
 
An inevitable consequence of the worldwide increased consumption of pharma-
ceuticals over the past decades is the high levels of their discharge into the aquatic envi-
ronment (Ebele et al., 2017; Lapworth et al., 2012). Although the ecological risk assess-
ment of these chemicals is still on its infancy, a limited number of examples highlight their 
disruption potential. The best-documented examples of the high impact caused by envi-
ronmental concentrations of pharmaceutical in ecosystems are the diclofenac and ethi-
nylestradiol (EE2) (EEA, 2010). Diclofenac, an anti-inflammatory drug used in veterinary, 
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was responsible for 95% decline of the vulture India population due to renal failure (EEA, 
2010; Green et all., 2004; Swan et al., 2006).  EE2, a synthetic estrogen constitutive of 
contraceptive pills, was found to be a powerful endocrine disruptor due to its ability to in-
duce feminizing effects in several organisms, particularly male fish, at ng/L concentrations 
(EEA, 2010; Soares et al., 2009).  
Despite these two well documented examples of the ubiquitous nature of pharma-
ceuticals in the terrestrial/aquatic ecosystems, most of the ecotoxicological studies with 
pharmaceuticals only report acute toxicity effects. Such data alone are not suitable to ad-
dress the actual environmental effects of pharmaceuticals, as their concentrations in the 
wild are too low to pose acute toxicity risk (Dahl et al., 2006, Fent et al., 2006). Further-
more, aquatic organisms are chronically exposed to pharmaceuticals for many genera-
tions (Arnold et al., 2014; BIO Intelligence Service, 2013; Fent et al., 2006). Moreover, as 
previously mentioned, in contrast to other chemicals, pharmaceuticals are designed to be 
bioactive molecules and hence are expected to target specific signalling pathways (BIO 
Intelligence Service, 2013; Fent et al., 2006). Taking in consideration that many signalling 
pathways may be conserved across different phyla, these chemicals may elicit biologically 
active effects in a broad range of organisms (Fent et al., 2006; Santos et al., 2016). In-
deed, one of the current limitations in aquatic toxicity assessment is that the mode of ac-
tion (MOA) of toxicants is frequently overlooked (Santos et al., 2016). Therefore, there is a 
need to address the long term-effects of pharmaceuticals as well as identify their MOAs in 
representative aquatic taxa.  
 
1.1.4. Hypolipidemic pharmaceuticals  
 
Health problems such as overweight and obesity have been increased exponen-
tially over the years, mainly in developed countries (Arnold et al., 2014). These diseases 
are frequently associated with other health problems, such as elevated plasma cholester-
ol, coronary heart disease, and consequently the risk of myocardial infarction (Allison & 
Saunders, 2000; Istvan, 2003; Ribeiro et al., 2015). 
Hypolipidemic drugs are divided in two groups, statins and fibrates. Statins are one 
of the most prescribed pharmaceuticals worldwide for reduction of cholesterol (Al-Habsi et 
al., 2016; Fent et al., 2006; Santos et al., 2010). These pharmaceuticals are able to de-
crease the endogenous production of cholesterol by direct competition with the enzyme 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) (Fent et al., 2006; Key et al., 2008; 
Santos et al., 2010).  
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1.1.4.1.  Cholesterol, statins and human health 
Cholesterol is a 27-carbon, tetracyclic molecule (Burg & Espenshade, 2011) which 
is synthetized from acetyl – CoA in nearly every cell of the organism. It is essential for 
many functional processes in living organisms such as structural component of cell mem-
branes, maintaining its stability and fluidity, and also functions as a precursor of all steroid 
hormones as well as bile acids and vitamin D (van der Wulp et al., 2013). High levels of 
cholesterol, a medical condition known as hypercholesterolemia, can induce several car-
diovascular diseases such as atherosclerosis, stroke and myocardial infarction, as well as 
type II diabetes (Goedeke & Fernández-Hernando, 2012; van der Wulp et al., 2013). The 
increased incidence of this type of diseases led to an urgent need of developing pharma-
ceuticals able to decrease the cholesterol levels. In the 1970s, Akira Endo and his team 
isolated the first statin, mevastatin, from Penicillium citrinum, a potent inhibitor of HMG-
CoA reductase (HMGCR), an essential enzyme in the cholesterol biosynthetic pathway, 
that was able to significantly decrease the cholesterol levels in both experimental animals 
and patients with hypercholesterolemia (Burg & Espenshade, 2011; Endo, 1992; Endo et 
al., 1976a; Endo et al., 1976b).  This revolutionary discovery allowed treating the high lev-
els of cholesterol in humans. Therefore, several HMGCR inhibitors, i.e. statins, started 
being developed and by 1990, three new statins, namely lovastatin, simvastatin, and 
pravastatin, have been approved and marketed in several countries and are still currently 
used by millions of patients (Endo, 1992). Through the years, statins´ treatment has been 
shown to decrease and prevent cardiovascular diseases associated with increased lipid 
content in the bloodstream, demonstrating that the treatment with these pharmaceuticals 
increase health and quality of life (Grover et al., 2014). 
 
1.1.5. Statins in the mevalonate pathway 
 
Due to its importance for physiological processes, vertebrate cells are able to ob-
tain cholesterol through a combination of dietary source, uptake from the bloodstream, 
and de novo synthesis (Burg & Espenshade, 2011). These cells developed a feedback 
regulation mechanism in two sequential enzymes, HMG-CoA synthase (HMGS) and 
HMGCR, in the mevalonate (MVA) pathway in order to achieve a balance between these 
sources of cholesterol income and avoid overaccumulation (Goldstein & Brown, 1990).  
Cholesterol is synthesized in the endoplasmic reticulum (ER) and cytoplasm in almost 
every cells in the organism from acetyl-CoA in the MVA pathway (Goedeke & Fernández-
Hernando, 2012).  Due to its importance for cholesterol regulation, as well as many other 
essential molecules resulting from the MVA pathway, it has been exhaustively studied 
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through the years (Burg & Espenshade, 2011). Cholesterol production from acetyl-CoA 
requires the action of 20 different enzymes, with HMGCR serving as the primary point of 
regulation of the entire pathway (Burg & Espenshade, 2011).  The upper part of MVA 
pathway has great importance, since it is the main target of regulation of the whole path-
way. The first step involves the synthesis of acetoacetyl-CoA from acetyl-CoA, which then, 
through the action of the enzyme HMGS, will form HMG-CoA. The binding of HMGCR to 
HMG-CoA triggers the key reaction of the whole pathway, thus producing MVA (Figure 3). 
Once MVA is produced, several more reactions occur, giving rise to two branches origi-
nated from farnesyl pyrophosphate. Squalene synthesis gives birth to the sterol branch, 
while the production of geranylgeranyl pyrophosphate lead to the isoprenoid branch (see 
Figure 3). This second branch produce essential non-sterol molecules, such as heme A, 
dolichol, ubiquinone and prenylated proteins, which are involved in several biological func-
tions such as growth and metabolism. Endogenous production of cholesterol is also tightly 
controlled by the sterol regulatory element binding protein 2 (SREBP2), which is involved 
in the feedback mechanism regulation of this pathway. When cholesterol levels decrease, 
SREBP2 is activated, increasing the expression of HMGCR as well as low density lipopro-
tein (LDL) receptors in hepatocyte membranes, thus increasing cholesterol biosynthesis 
and uptake, respectively (Al-Habsi et al., 2016). The LDL receptors capture LDL choles-
terol from the blood, lowering serum LDL cholesterol. This feedback mechanism is also 
observed after statin treatment, which partly explains how serum LDL cholesterol de-
crease after statin treatment (Al-Habsi et al., 2016; Altekin et al., 2002; Fent et al., 2006).  
For a long time, investigators speculated the precise target of cholesterol biosyn-
thesis regulation. By 1960, Siperstein and Guest (1960) discovered that the  conversion of 
HMG-CoA to mevalonate (MVA), was the responsible reaction for the cholesterol feed-
back control. It was then discovered that HMGCR was the enzyme responsible for this 
conversion, and the administration of statins, i.e. HMGCR inhibitors helped clarifying the 
exact role of this enzyme in the MVA pathway (Eisa-beygi et al., 2013). 
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Figure 3. Schematic representation of the interactions of statins in the mevalonate path-
way in vertebrates. Statins compete with HMG-CoA for the binding site on HMGCR there-
by inhibiting its activity and reducing cholesterol synthesis. SREBP2 is then activated 
leading to an increase of HMGCR and LDL receptors expression in order to increase cho-
lesterol biosynthesis. Apart from sterol branch (cholesterol synthesis), other isoprenoids 
(heme A, dolichol, ubiquinone) and prenylated proteins are synthesized via the mevalo-
Isoprenoid branch Sterol branch 
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nate pathway by geranylgeranyl pyrophosphate. Adapted from (Al-Habsi et al., 2016; 
Goldstein & Brown, 1990; Santos et al., et al., 2016). AACT – acetoacetyl-CoA thiolase; 
HMGS – 3-hydroxy-3-methylgrutaryl-CoA synthase; HMGCR - 3-hydroxy-3-
methylgrutaryl-CoA reductase; SQS – squalene synthase; FPPS – farnesyl diphosphate 
synthase; CYP51 – lanosterol 14α-demethylase; DHCR7 – 7-dehydrocholesterol reduc-
tase; SREBP2 – sterol regulatory element-binding protein 2; LDL – low density lipoprotein. 
 
Statins are hypocholesterolaemic drugs, one of the most prescribed classes of 
pharmaceuticals in the world (Neuparth et al., 2014; Santos et al., 2016). Statins compete 
with HMG-CoA for the active binding site in the enzyme HMGCR. Once bound to the en-
zyme, statins alter its conformation, thereby inhibiting its function (Al-Habsi et al., 2016; 
Istvan, 2003). Moreover, part of statins structure have a component which resembles 
HMG-CoA, being yet more hydrophobic and more bulky than the natural substrate (Istvan, 
2003). These characteristics make statins affinity to the HMGCR about three orders of 
magnitude greater than the natural substrate, easily inhibiting the entire pathway by deny-
ing the MVA synthesis (Moghadasian, 1999). In addition to the cholesterol lowering action, 
statin treatment has been shown to have other pleiotropic effects in mammals such as an-
ti-inflammatory, antioxidant, Immunomodulatory, angiogenesis promotion and increase in 
bone formation (Grover et al., 2014). Evidence of its beneficial effects in the treatment of 
certain types of cancer and Alzheimer’s disease has also been growing (Chen et al., 
2016; Schointuch et al., 2014). However, statins have also been shown to produce sever-
al undesirable side effects in humans and other mammals. Grover et al (2014) compiled a 
list of statins adverse effects that included myopathy, hepatotoxicity, diabetes mellitus, 
erectile dysfunction, prostate cancer and pro-inflammatory, neurologic, pulmonary and 
ophthalmological manifestations. Due to its involvement on high incidence of rhabdomyol-
ysis, cerivastatin was the first statin removed from European and American pharmaceuti-
cal markets in 2001 for safety purposes (Grover et al., 2014). Many of these effects may 
be a consequence of the inhibition of the upper MVA pathway, which not only block cho-
lesterol production, but also other essential molecules resulting from the isoprenoid 
branch previously mentioned (Gee et al., 2015; Grover et al., 2014). 
Statins are generally rapidly degraded in the liver. This organ is able to metabolize 
approximately 50 - 95% of the hepatic statins (Evans & Rees, 2002). The main rout of re-
moval involves the activity of Cytochrome P450 (CYP) 3A subfamily. However it has been 
shown that they can also suffer glucuronidation (Evans & Rees, 2002; Fujino et al., 2004).  
Although this drug have low systemic availability, due to its rapid metabolization, it has 
high biological activity since hepatocytes are the main site of action of statins (Evans & 
Rees, 2002). 
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1.1.6. Effects of Simvastatin in the aquatic environment 
 
Statins, mainly SIM, are amongst the most prescribed pharmaceuticals in the 
western countries as primary treatment for hypercholesterolemia by decreasing serum  
LDL-cholesterol levels (Burg & Espenshade, 2011; Estey, 2007; Neuparth et al., 2014). 
Annual reports from INFARMED, a Portuguese entity responsible for the supervision of 
the pharmaceutical sector, indicated that over more than 12 years, SIM has been the most 
sold statin in the Portuguese national health system (NHS) and its usage has been in-
creasing over the years (Figure 4) (INFARMED, 2017). It is also important to note that 
SIM introduction in Europe is relatively recent. Taking these facts into account, it is almost 
certain that SIM increasing sales and continuous emissions will increase its concentra-
tions in aquatic ecosystems (Ribeiro et al., 2015).  
 
 
Figure 4. Comparison of the 12 years evolution of number of packages of the main phar-
maceutical sold (Paracetamol, Metformin, Nimesulide and Simvastatin) in the Portuguese 
National Health Service (NHS). 
 
Several authors have reported the presence of SIM in WWTPs worldwide (Table 
1). However little information about surface waters concentration is available with a pre-
dicted environmental concentration of 369.8 ng/L in Portuguese waters (Pereira et al., 
2015). Influent waters of WWTP has been shown to carry high amounts of this pharma-
ceutical and as a consequence of the lack of efficient water treatments in these facilities, 
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
4500000
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
N
U
M
B
E
R
 O
F
 P
A
C
K
A
G
E
S
 I
N
 T
H
E
 P
O
R
T
U
G
U
E
S
E
 
N
H
S
YEAR
Simvastatin
Paracetamol
Metformin
Nimesulide
 
 
12 
 
effluents end up also carrying substantial amounts of this compound. A study performed 
by Pereira et al. (2016) in several Portuguese WWTPs revealed that in certain cases in-
fluents could carry up to 8 900 ng/L of SIM and WWTP effluents ended up discharging 
1 500 ng/L of SIM into receiving water bodies (Table 1). 
 
Table 1. Detected SIM concentrations (ng/L) in several WWTP (influents and effluents) 
across the world. Non detected concentrations are marked with n.d. 
Provenience Detected concentrations 
(ng/L) 
References 
WWTP influent 4.0 (Miao & Metcalfe, 2003) 
WWTP effluent 1.0 
WWTP influent 1 230.0 (Ottmar et al., 2012) 
WWTP effluent 90.0 
WWTP influent 976.0 (Sousa, 2013) 
WWTP effluent 197.0 
WWTP influent 8 500.0 (Pereira et al., 2015) 
WWTP effluent 369.8 
WWTP influent 40.0 (Verlicchi et al., 2012) 
WWTP effluent n.d. 
WWTP influent 798.0 (Kasprzyk-Hordern et al., 
2009) WWTP effluent 20.0 
WWTP influent 8 900.0 (Pereira et al., 2016) 
WWTP effluent 1 500.0 
 
The main concern of the increase consumption of SIM is its environmental persis-
tence, toxicity, potency, and biological activity in aquatic ecosystems. Furthermore, SIM 
have a high Log Kow of 4.68, which might indicate that it may bioaccumulate in aquatic or-
ganisms (Santos et al., 2016). The fact that SIM is highly lipophilic also makes this statin 
able to enter tissues of aquatic organisms through direct diffusion, while other statins only 
enter their target tissues in the liver where receptors are available. Its lipophilic nature is 
responsible for SIM ability to cross the blood-brain and placenta barriers, which more hy-
drophobic statins are not able (Moghadasian, 1999).  
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Santos et al. (2016) demonstrated that the catalytic domains of HMGCR through-
out metazoans are highly conserved in respect not only to the interaction with HMG-CoA, 
but also its interactions with statins. This indicates that statins should be able to inhibit the 
enzyme HMGCR in several taxa. However we need to be cautious, since several taxa do 
not show a conservation of its downstream MVA pathways. This means that effects ob-
tained in vertebrates after statin treatment, for example, could not be the same in arthro-
pods, which lack the sterol branch in the MVA pathway (Santos et al., 2016). 
 
Table 2.  Simvastatin toxicity data for several groups of organisms. Concentration ex-
pressed as µg/L 
Organisms SIM concentra-
tion 
(µg/L) 
Duration Observed effects Reference 
Algae     
Dunaliella  
tertiolecta 
22 800 (aEC50) 96h Growth inhibition 1 
Arthropods     
Plaemonetes 
pugio 
1 180 (bLC50) 
1 250 (cLOEC) 
96h Decreased larvae 
survival 
2 
 10 000(LC50) 96h Decreased adult 
survival 
2 
Nitocra  
spinipes 
810 (LC50) 
0.16 (LOEC) 
Till the 3rd 
copepodite 
stage 
Decreased growth 
rate 
3 
Gammarus  
locusta 
0.32 35 days Decreased repro-
ductive capability 
4 
Echinoderms     
Paracentrotus 
lividus 
>5 48h Decreased larval 
length 
5 
 >2 48h Increase in the per-
centage of total ab-
normalities 
5 
Fish     
Oncorhynchus 
mykiss 
167.4 – 
167 429.6 
24,48, and 
72 h 
Cytotoxicity to pri-
mary hepatocytes, 
reduced metabolic 
6 
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activity and mem-
brane stability  
Danio rerio 837.1 80h Embryos exhibited 
developmental ar-
rest, blunted axis 
elongation, mis-
shapen somites, 
head and axial ne-
crosis 
7 
 500 80h Embryos with in-
creased percentage 
of total abnormali-
ties.  
5 
Notes: aEC50 – median effective concentration; bLC50 –median lethal concentration; 
cLOEC – lowest observed effect concentration. References: (1) - (DeLorenzo & Fleming, 
2008); (2) - (Key et al., 2008); (3) - (Dahl et al., 2006); (4) - (Neuparth et al., 2014); (5) - 
(Ribeiro et al., 2015); (6) - (Ellesat et al., 2010); (7) - (Anderson et al., 2011) 
 
Previous studies have reported detrimental effects of SIM in aquatic organisms at 
several levels of biologic organization such as impairment of embryo development and 
disturbances at reproductive level (delay in gonadal maturation, for example), behavioural 
abnormalities, and even mortality for some vertebrate and invertebrate aquatic organisms 
(Table 2) (Cunha e al., 2016; Ribeiro et al., 2015; Neuparth et al., 2014; Ellesat et al: 
2011; Ortiz de Garcia et al., 2014). Although SIM environmental concentrations generally 
range from ng/L to µg/L, most of the studies performed regarding SIM toxic potential are 
based on acute exposures with much higher concentrations than those found in the envi-
ronment (Table 2).  
Studies with other statins have also reported that these drugs were able to de-
crease cholesterol and triglycerides (TGL) levels in fish species, and modulate expression 
rates of genes related to cholesterol biosynthesis, as well as genes involved in the bio-
transformation and efflux of statins (Al-Habsi et al., 2016; Cunha et al., 2016). Larvae de-
velopmental arrest and adult sterility in Caenorhabditis elegans, were observed after ex-
posure to 558 mg/L of atorvastatin (ATV) (Mörck et al., 2009), the same compound was 
also able to induce genotoxicity in adult zebrafish (5-14 days; 0.2 – 10 µg/L) (Rocco et al., 
2010), and up-regulation of genes involved in oxidative stress response, biotransformation 
and membrane transport in rainbow trout (Ellesat et al. 2010). The mechanism of action 
that underlies statins toxicity in non-target organisms is yet not fully understood (Gee et 
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al., 2015). Chronic toxicity data for SIM is also still very scarce, mainly for aquatic verte-
brates. There is an urgent need for the performance of long-term exposure assays inte-
grating several ecological relevant endpoints from individual to sub-individual level which 
may help clarifying the mechanism(s) underlying statins toxicity to non-target organisms 
exposed to this compound through their entire life-cycle. In fact, since several studies 
have demonstrated effects in development and reproduction, these two endpoints should 
be assessed after a long-term exposure to SIM due to its high importance at population 
level. Lipids and mRNA contents of genes related to the cholesterol biosynthetic pathway, 
such as hmgcr, srebp2 and other ones involved in the sterol branch should also be ana-
lysed since almost only acute data is available for these endpoints. A better understanding 
of the MOA of statins through the assessment of these endpoints after long-term exposure 
at low concentrations is also needed. The integration of several key endpoints is important 
to better understand the real implications of chronically exposed aquatic vertebrates to low 
concentrations in the environment and anticipate effects at population level.  
 
 
1.2.  Model Species: zebrafish (Danio rerio) 
 
In order to obtain ecologically relevant data to assess the potential risk of SIM in 
aquatic ecosystems, one of the key challenges is to choose an appropriate model organ-
ism to conduct chronic bioassays. Danio rerio is considered a good choice since it is con-
sidered a good representative of higher trophic levels in ecotoxicity studies. Over the past 
thirty years, D. rerio has emerged as a vertebrate model for drug development, physiolo-
gy, genetics (zebrafish genome has been completely sequenced: 
http://www.ensembl.org/index.html), development, and ecotoxicological studies (Fang & 
Miller, 2012; Lawrence, 2007). There are several attributes that make this species an ideal 
model for ecotoxicological studies, offering technical and practical advantages for studying 
biological processes, effects and mechanisms (Segner, 2009).  Fish models are generally 
considered good organisms to be used in toxicological studies due to their sexual plastici-
ty, easy manipulation and exposure to contaminants in laboratory. The species size, ro-
bustness, multiple progeny from a single mating and easy maintenance under laboratory 
conditions are advantages for its use as bioassay organism (Fang & Miller, 2012; 
Lawrence, 2007; Soares et al., 2009). In addition, a close phylogenetic relationship be-
tween teleost fishes, such as D. rerio, and mammals can be observed. Comparison of ge-
nome sequences revealed highly conserved genes in several signalling pathways, such 
as inflammation, oxidation and lipid metabolism (Fang & Miller, 2012). Studies have 
demonstrated high similarities in the functionality of certain genes and proteins when 
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compared to its mammalian homologs (Fang & Miller, 2012; Ho et al., 2004). In particular, 
D. rerio have been shown to share a high amount of genetic identity with humans. Almost 
70% of human genes have one zebrafish orthologue, facilitating extrapolation of data to 
other vertebrates (Howe et al., 2013; Santoro, 2014). 
Commonly known as zebrafish, D. rerio is a small freshwater teleost fish belonging 
to the Cyprinidae family. This species is native from South Asia, being distributed across 
parts of India, Bangladesh, Nepal, Myanmar, and Pakistan (Lawrence, 2007). Adult 
zebrafish can reach up to 30-40 mm long and weight 300-500 mg (Fang & Miller, 2012). 
When adult, this species present a slight sexual dimorphism upon reaching sexual maturi-
ty (Figure 6). Males present a slender figure with a slight yellow coloration on its caudal fin 
and belly, whereas females have a more silvery aspect and swollen bodies due to their 
high egg production (Lammer et al., 2009). 
 
 
Figure 5.  Zebrafish (Danio rerio) female (A) and male (B). 
 
 In laboratory conditions, zebrafish is able to breed through the whole year. 
Zebrafish spawns at dawn, with a frequency of about three days, and the daily number of 
eggs laid by a female is quite variable, ranging from 100-500 eggs in each occasion. 
Spawning occurs in the first 30 to 60 minutes after the beginning of the light period, so 
large numbers of eggs at similar stages of development are available and easily collected. 
Since zebrafish embryos develop outside their mothers favours its manipulation and incu-
bation in 24 well plates. In addition, their rapid development, approximately 3 days at 
28.5°C, and optimal transparency are ideal for developmental studies and since its stages 
of development are well known, embryos can be used in toxicity assays (Kimmel et al., 
1995; Segner, 2009).  
 
 
 
A 
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1.3. Objetives 
 
The present work aims at investigating several biological responses in Danio rerio, fol-
lowing chronic exposure to environmental relevant concentrations of SIM (ng/L). Here we 
integrate multiple key endpoints at individual level (survival, growth, reproduction, and 
embryonic development), which might give insights over possible adverse long term ef-
fects at population level, with biochemical markers of lipid homeostasis (cholesterol and 
triglycerides) and molecular analysis (mRNA levels of srebp2, hmgcra, cyp51, and dhcr7 
genes). These sub-individual endpoints should give more information regarding SIM MOA 
at relevant environmental concentrations.  
The aim is to increase SIM database, in order to better predict potential harmful effects 
in environmental populations after long term exposure. 
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2. Material and Methods 
2.1. Chemicals 
Simvastatin (SIM, CAS 79902-63-9 - 97.0 % purity) was purchased from Sigma-
Aldrich. The SIM stock and working solutions were prepared in acetone (ACET, 99.0 %), 
purchased from BIOCHEM chemopharma, with a maximum ACET concentration of 
0.0002%. The prepared solutions were stored in the dark at -20°C. 
 
2.2. Zebrafish maintenance  
Juvenile wild-type zebrafish with 50 days were obtained from Singapore local sup-
pliers. Animals were acclimated to controlled laboratory conditions, in 250 L aquarium with 
dechlorinated filtered and aerated water. During this period, fish were kept at 28 ± 1°C, 
photoperiod at 14 h light:10 h dark and fed, ad libitum,  three times per day with commer-
cial fish diet Tetramin (Tetra, Melle, Germany). These conditions were maintained for 15 
days until the beginning of the chronic bioassay. 
 
2.3. Chronic toxicity bioassay 
The chronic bioassay were carried out at Biotério de organismos aquáticos (BO-
GA) located at CIIMAR. The experiment was subject to an ethical review process carried 
out by CIIMAR animal welfare body (ORBEA) prior to the experimental work is started. 
The bioassay was performed in compliance with the European Directive 2010/63/EU on 
the protection of animals used for scientific purposes, and the Portuguese ‘Decreto Lei’ 
113/2013. 
Juvenile zebrafish were allocated to 30 L aquaria in a flow-through system. The 
water flow was maintained at 1.08 L per hour using a peristaltic pump (ISM 444, IS-
MATEC) provided with dechlorinated tap water (carbon activated filtration) and the water 
level in each aquarium was maintained at 27 L. The bioassay was performed during 90 
days. Each aquarium had 25 juvenile zebrafish, with a water temperature of 28 ± 1°C, 
14:10 h (light:dark) photoperiod and a mean ammonia concentration of 0.08 ± 0.04 mg/L. 
Throughout the bioassay, the amount of food distributed was adjusted according to fish 
development and size. The food consisted in commercial fish diet Tetramin (Tetra, Melle, 
Germany) twice a day, supplemented with 48 hours live brine shrimp (Artemia spp) since 
one week before the start of reproduction. The experiment consisted of six treatments in 
duplicate: a control (dechlorinated water); a solvent control (0.0002% ACET), and four 
SIM treatments: 12.8 ng/L, 64 ng/L, 320 ng/L, and 1600 ng/L concentrations. The selec-
tion of these SIM concentrations was based in previous studies (Neuparth el al., 2014), 
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that are environmentally relevant. A SIM stock solution was prepared in ACET with a con-
centration of 4 mg/mL and an aliquot of this stock was serially diluted in order to prepare 
the SIM working solutions. These solutions were stored in obscurity at -20°C. Based on 
preliminary tests, in order to maintain exposure concentrations, the working solutions were 
dosed directly into the water twice a day (in the morning - T 0 h - and in the afternoon - T 
8 h), in a volume that was equivalent to the water renewal during that period. 
 
2.4. Reproductive capability 
Reproductive capability studies were performed 70 days after the beginning of the 
chronic exposure for all the tested groups. Reproductive success was assessed through 
the evaluation of two factors: fecundity, i.e. number of embryos per female per day, and 
percentage of viable/fertilized eggs per female per day. In the afternoon, before the be-
ginning of the trials, each aquarium was divided in two and in each division a suspended 
cage, with a bottom net covered with marbles, was fixed in order to mimic the natural sub-
strate. Males and females were equally distributed through the cages in order to have the 
same sex ratio in each treatment (four sub-replicates per treatment) (Figure 6). The Sex 
ratio was determined by visual observation of each animal which was confirmed at the 
end of the bioassay, by stereomicroscope gonads observation.  
 
 
Figure 6. Representation of the breeding setup for reproductive capability assay. A – im-
ages of the actual setup and B – schematic representation of the setup. 
 
During five consecutive days, (1-1.5 hour after sunlight) breeding fish were re-
moved, the eggs were collected from the bottom of the tank by siphoning, cleaned and 
conserved in 70% ethanol for further counting and determination of the percentage of via-
ble eggs (Figure 7). 
A
  A 
B
  A 
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Figure 7.  Stereomicroscope view of embryos stored in ethanol 70%. It is possible to dis-
tinguish viable embryos (B) from non-viable (A) through its transparency. 
 
2.5. Embryogenesis studies 
 
Embryogenesis studies were carried out based on the most recent OECD guide-
line for fish embryo acute toxicity (FET) test (OECD test 236, 2013), with slight modifica-
tions. During the reproductive trials, 15 embryos with 1-1.5 hpf (hours post fertilization) 
from each treatment sub-replicate were randomly separated, cleaned and placed in 24 
well plates, one per well with 2ml of clean dechlorinated water (Figure 8). The 24 well 
plates were randomly maintained on a water bath at 26.5 ± 0.5 °C during 80 h. Embryos 
were checked every day for mortality and water was not changed since it had no contami-
nants. At the end of the 80h embryos were observed under a stereomicroscope for anom-
alies detection and abnormal embryos were photographed. Morphological abnormalities 
on head, tail, eyes or yolk-sac, pericardial edema, abnormal cell growth and developmen-
tal arrest were recorded as present or absent. Heart rate was evaluated in four embryos 
per plate using a stop-watch during 15s, restarting the counting if the embryo moved. 
 
 
Figure 8. Schematic representation of the disposition of embryos in the 24 well plate. 
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2.6. Sampling 
 
At the end of the chronic bioassay, animals were sacrificed with an anesthetizec 
overdose of 300 mg/L  tricaine methanesulfonate (MS-222) with the addition of the same 
amount of sodium bicarbonate, in order to prevent the acidification of the solution and to 
guarantee minimum pain for the animals. All animals were measured and weighted (Fig-
ure 9) for Fulton’s condition factor determination, which is calculated from the relation be-
tween length and weight according the equation: K = (weight / lenght3)×100 (Nash et al., 
2006). 
Livers, gonads and cerebrum of randomly 15 males and 15 females of each treat-
ment were collected and preserved in RNALater for gene expression analysis. Livers and 
muscle from the remaining animals were frozen in liquid nitrogen and stored at - 80°C for 
further cholesterol and TGL quantification. 
 
 
 
Figure 9. Measurements of zebrafish length (A) and weight (B). Collecting tissues for 
gene expression and cholesterol/TGL quantification (C)  
 
 
(A) (B) 
(C) 
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2.7. Gene expression 
2.7.1. RNA isolation and cDNA synthesis 
 
Liver samples of the different treatments, stored in RNALater, were used to isolate 
total RNA via the Illustra RNAspin Mini RNA Isolation kit (GE Healthcare), according to the 
manufacturer’s protocol. Approximately 3 mg of tissue was homogenized, with the help of 
ceramic beads on a Precellys 24 homogenizer to lyse the cells. The homogenate was 
then filtered to reduce the viscosity and clean the lysate. The RNA was then bonded to the 
silica membrane with the addition of ethanol (70%), and the addition of DNaseI digested 
the DNA present in the silica membrane. The silica membrane was then washed with two 
different buffers in order to remove salts, metabolites and macromolecular cell compo-
nents. Finally, the membrane contained pure RNA was eluted with RNase-free water.  
RNA quantification was performed by the measurement of optical density with a 
Take3TM on a microplate reader (Biotech Synergy HT) coupled with the software Gen5 
(version 2.0). RNA quality was verified by electrophoresis in 1.5 % agarose gel and 
through the measurement of the ratio of absorbance at λ260/ λ280 nm. All isolated RNA 
samples were stored at - 80°C until further use. Total cDNA was generated from 1μg of 
total RNA extracted from the liver using the iScriptTM cDNA Synthesis Kit (Bio-Rad). Due 
to time constrains, brain and gonads were not processed for genetic analysis.  
 
2.7.2. qRT-PCR 
 
Several enzymes involved in the mevalonate pathway, were selected accordingly 
to their roles in the cholesterol biosynthesis to evaluate their gene expression in each of 
the 6 treatments used (control, solvent control, 12.8, 64, 320, and 1600 ng/L SIM concen-
trations). The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) was the first gene se-
lected, because it is the responsible for the limiting step in the mevalonate pathway, and 
statins act as competitive inhibitors of HMGCR. According to the previous studies on the 
gene tissue distribution, we chosen to assess 3-hydroxy-3-methylglutaryl-CoA reductase a 
(hmgcra) instead of hmgcrb, since the first one is predominant in the liver and the second 
in the brain (Al-Habsi et al., 2016). Other two genes, lanosterol 14α-demethylase (cyp51) 
and 7-dehydrocholesterol reductase (dhcr7) were chosen as intermediate genes in the 
MVA pathway in order to evaluate changes on downstream of HMGCR after its inhibition 
(Figures 3 and 10). Moreover, mRNA levels of the sterol regulating element-binding pro-
tein 2 (srebp2) were also assessed to verify if a feedback mechanism carried out by its 
enzyme would occur. 
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Figure 10. Schematic representation of the sites of action of the selected genes on the 
MVA pathway. Circles and arrows indicate the target genes. A – upper and middle section 
of the pathway; B – lower section of the MVA pathway. 
 
Gene expression profiles of srebp2, hmgcra, cyp51, and dhcr7 were assessed by 
means of quantitative real time PCR (qRT-PCR).  Ribosomal protein L8 (rpl8) was used 
as reference gene, since it expression levels did not change significantly across treat-
ments. All the primers were already described by other authors (Table 3). The cDNA of 
liver samples of each treatment (n=8) were amplified in duplicated using the Mastercycle 
ep realplex system (Epperndorf) in 96-well optical plates, containing 10 µL of NZY qPCR 
Green Master Mix (2x) (nzytech), 0.8 µL of each primer (forward and reversed), 2 µL of 
cDNA at 100 nmol and 6.4 µL of water in order to reach a final reaction volume of 20 µL. 
On each plate, a nontemplate control was included. In order to determine the efficiency of 
the reaction, a two-step qRT-PCR was performed:  95°C of initial denaturation for 3 min, 
followed by 40 cycles of amplification with a denaturation at 95°C for 15 seconds and 
combined annealing and extension at 58 - 62°C, depending on the pair of primers, for 25 
seconds (Table 3). A melting curve (from 55°C to 95°C) was generated in each run to con-
firm the specificity of the reactions. In order to confirm the product, the PCR products were 
analysed by electrophoresis in 2% agarose gel to check the presence of single bands with 
expected size between 134 and 199 bp, depending on the pair of primers (Table 3). The 
PCR efficiency for the genes of interest and the reference gene was determined by a 
standard curve, using six serial dilutions of cDNA pools of all samples (from 0.064 to 200 
ng of cDNA). The minimum efficiency obtained was 94% (Table 3).  
Relative change in transcription abundance of target genes was normalized to 
rp18 and calculated using the 2-∆∆Ct analysis method. Control expression levels (acetone 
treatment) were normalized to 1 and data were then expressed as fold changes of the 
solvent control group.  
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Table 3. Primers, forward (F) and reversed (R), and parameters used in the qRT-PCR for gene expression quantification in the liver of D. rerio. 
Gene Sequence (5’ – 3’) Expected 
band size 
(bp) 
Combined anneal-
ing and extension 
temperature (°C) 
Average 
efficiency 
(%) 
Reference 
srebp2 F: GAGATAAAGTGGACCCCATCG 
R: CAGAAACTCCAGAACCCCAG 
134 60 99 (Al-Habsi et al., 2016; 
Craig & Moon, 2011) 
hmgcra F: TCGTGGAGTGCCTGGTGATTGGT 
R: TGGGTCTGCCTTCTCTGCTCTCTC 
177 62 98 (Mu et al., 2015b) 
cyp51 F: GCTCGGAGACACTCAGACACATCTT 
R: AGCAGAACTGAAGTCAGGCTCATCT 
138 60 96 (Mu et al., 2015b) 
dhcr7 F: GAGGAGTTCAGGATGGTGCCCGTA 
R: GTGGACACAGCATAGCCGAGGATG 
199 60 94 (Mu et al., 2015b) 
rpl8 F: TTGTTGGTGTTGTTGCTGGT 
R: GGATGCTCAACAGGGTTCAT 
136 58 94 (Lyssimachou et al., 2015) 
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2.8. Lipid extraction and Cholesterol and Triglycerides quantification 
 
Lipids were extracted from the liver samples stored at -80°C using a low toxicity 
solvent extraction protocol, adapted from Schwartz and Wolins (2007). The tissues were 
homogenized in 10 mM PBS buffer pH 7.4, containing 10mM EDTA (10 mg of tissue per 
1mL buffer with two ceramic beads) on a Precellys 24 homogenizer. 500 µL of homoge-
nate were then transferred, in duplicates, to test glass vials containing 5 mL of isopropa-
nol/hexane solution (4:1 proportion). The samples were vortexed for 1 minute and incu-
bated at room temperature in the dark, with constant shaking for 2 hours. In order to avoid 
lipid peroxidation, vials were passed always through nitrogen current before closing. After 
the incubation period, samples were washed with 2 mL of petroleum ether/hexane (1:1) 
solution. Vials were again vortexed for 1 min and left in the dark, at room temperature, for 
10 minutes. The phases were then separated by adding 1 mL of Milli-Q H2O, vortexed for 
1 min, incubated at room temperature in the dark, , with constant shaking for 20 min and 
centrifuged at 1000 × G, for 10 min. The upper phase containing the lipids was collected 
into new vials and evaporated to dryness under nitrogen current. Dried extracts were then 
stored at - 20°C until cholesterol and triglycerides quantification. 
Dry extracts were re-suspended in 100 µL of isopropanol and sonicated for 15 
minutes at room temperature in ultra-sound bath Bandelin Sonorex RK100H. Quantifica-
tion of cholesterol and triglycerides was performed through enzymatically colorimetric as-
says using Infinity Cholesterol Liquid Stable reagent and Infinity Triglycerides Liquid Sta-
ble Reagent, respectively, both purchased from Thermo scientiphic, Biognóstica, Portugal 
and following the manufacturer’s protocol. Samples were measured in duplicates and ab-
sorbance determined at 490nm using a microplate reader (Biotech Synergy HT) coupled 
with software Gen5 (version 2.0). A standard curve was performed, in every run, for opti-
mal quantification. Cholesterol and Triolin standards, were prepared and subjected to 6 
serial dilutions (from 0.156251 to 5 mg/mL for cholesterol and 0.0625 to 2 mg/mL for tri-
olin). 
 
2.9. Simvastatin analytic quantification  
 
The actual concentrations of SIM was determined in each treatment three times 
during the bioassay: 30 minutes after the first contamination of the day with SIM (T0), 8 
hours after the first contamination (T1), and the final one 30 minutes after the second con-
tamination (T2). Two samples from each treatment (bulk samples from each replicate) 
were collected and stored at -20°C. The samples were then send to an external laboratory 
at the University of Santiago de Compostela, Spain to be analysed. These samples are 
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currently being processed and quantified by Liquid Chromatography - Tandem Mass 
Spectrometry (LC - MS/MS).  
 
2.10. Statistical analysis 
 
Data obtained from our study were checked for homogeneity of variances 
(Levene’s test) and normality (Kolmogorov-Smirnov test) and subsequently analysed by 
one-way ANOVA. Post-hoc comparisons were carried out using Fisher’s least significant 
difference (LSD) test. When no differences were found between control and solvent con-
trol groups, these were pooled and referred to as control.  For the gene expression, the 
control and solvent control groups were not pooled and all treatments were compared with 
solvent control group. Significant differences were set as p<0.05. All the statistics were 
computed with Statistica 13 (Statsoft, USA). 
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3. Results 
3.1.  Ecological endpoints 
3.1.1. Survival, growth and body weight 
Figure 11 shows the survival rates, and mean weight and length of zebrafish (Fig-
ure 12), males and females following 90-days exposure to 12.8 – 1600ng/L SIM. No sig-
nificant differences among treatments were observed in the mortality rate, almost 100% of 
the fish survived at the end of the bioassay (Figure 11). The males average weight was 
significantly lower in the highest SIM concentration tested (1600ng/L) in comparison with 
control groups. Males from 1600 ng/L SIM were 6.14% less heavy than males from control 
groups. In contrast, the weight of females, the length of males and females and the condi-
tion factor were not affected by SIM exposure. (Figure 12).  
 
 
Figure 11. Chronic effects on D. rerio survival after 90 days exposure to SIM. Error bars 
indicate standard errors. As no significant differences were found between control and 
solvent control groups, the data from these two treatments were pooled and referred to as 
control. 
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Figure 12. Chronic effects of SIM on weight (A), length (B) and Fulton’s condition factor 
(C) of D. rerio after an exposure of 90 days to Simvastatin. Error bars indicate standard 
errors; asterisks (*) indicate significant differences from the control group (p<0.05). As no 
significant differences were found between control and solvent control groups, the data 
from these two treatments were pooled and referred to as control. 
 
3.1.2. Reproductive capability 
Significant effects on the reproductive capability were observed for fecundity at the 
highest SIM concentration tested (Figure 13. A). All tested SIM concentrations exhibited 
an increase in the number of embryos per female per day, however only the 1600 ng/L 
SIM concentration differed significantly  from the control groups. The percentage of ferti-
lized eggs per day (from 92% in control groups to 98% in SIM 320ng/L concentration) did 
not exhibited significant alterations in any SIM concentrations (Figure 13 .B) 
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Figure 13. Chronic toxicity effects of SIM on D. rerio fecundity (A) number of embryos per 
female per day, and percentage of fertilized embryos (B) after 90 days of exposure. Error 
bars indicate standard errors; asterisks (*) indicate significant differences from the control 
group (p<0.05). As no significant differences were found between control and solvent con-
trol groups, the data from these two treatments were pooled and referred to as control. 
 
3.1.3. Embryogenesis  
After 70 days of SIM parental exposure, the embryos mortality rate at 80hpf 
ranged from 5% (320 ng/L SIM parental exposure) to 11.7% (1600ng/L SIM parental ex-
posure) with no significant differences among treatments (figure 14. A).  From all the ab-
normalities analysed, arrest in the development and the tail abnormalities occurred in the 
higher number, therefore we show these abnormalities in individual graphics while the re-
maining ones accounted for the total abnormalities. Several SIM treatments exhibited de-
velopmental arrest (Figure 14. C), however the differences from control groups were not 
significant. There was a significant increase in the percentage of tail abnormalities in low-
est concentrations, i.e. 12.8 and 64 ng/L, with 7.5% increase in both treatments, these 
abnormalities consisted in shortened and/or curled tails (Figure 15 and Figure 14. B). For 
total abnormalities (Figure 14. D), the lowest concentration (12.8 ng/L) also exhibited sig-
nificant differences when compared with control groups with 17.47% increase from control 
groups. SIM parental exposure was also able to significantly increase heart beat by 8.37 
bpm for 64 ng/L of SIM, relatively to control ones (Figure 14. E). 
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Figure 14. D. rerio mortality (A), embryonic abnormalities (B, C and D) and heart rate (E) 
at 80 hpf, after parental chronic exposure of SIM for 70 days. Error bars indicate standard 
errors; asterisks (*) indicate significant differences from the control group (p<0.05). As no 
significant differences were found between control and solvent control groups, the data 
from these two treatments were pooled and referred to as control. 
 
0
20
40
60
80
100
CTRL 12.8 64 320 1600
E
m
b
ry
o
 m
o
rt
a
lit
y
 (
%
)
SIM  Concentrations (ng/L)
0
20
40
60
80
100
CTRL 12.8 64 320 1600
T
a
il 
a
b
n
o
rm
a
lit
ie
s
 (
%
)
SIM concentrations (ng/L)
* *
0
20
40
60
80
100
CTRL 12.8 64 320 1600
D
e
v
e
lo
m
e
n
ta
l a
rr
e
s
t 
(%
)
SIM concentrations (ng/L)
0
20
40
60
80
100
CTRL 12.8 64 320 1600
T
o
ta
l 
a
b
n
o
rm
a
lit
ie
s
 (
%
)
SIM concentrations (ng/L)
*
0
20
40
60
80
100
120
140
160
CTRL 12.8 64 320 1600
H
e
a
rt
 r
a
te
 (
b
p
m
)
SIM concentrations (ng/L)
*
(A) (B)
) 
 (A) 
(C) (D) 
(E) 
 
 
37 
 
 
Figure 15. Tail abnormalities, at 80 hpf, after D. rerio parental exposure to SIM during 70 
days. Comparison between control (A), 12.8 ng/L (B) and 64 ng/L (C). 
 
3.2. Gene expression 
Both female (Figure 16) and male (Figure 17) D. rerio showed significant differ-
ences from the solvent control on their genes expression levels after 90 days of exposure 
to SIM. However males exhibited more changes than females. hmgcra and cyp51 mRNA 
expression levels produced non-monotonic dose-response curves (NMDRCs) for both 
sexes. In females, hmgcra mRNA was down regulated by 1.24 and 1.3 fold from the sol-
vent control treatment after exposure to 64 and 320 ng/L of SIM, respectively. Similarly, 
males also down regulated this gene expression by 1.58 and 1.32 fold in the same treat-
ments, respectively. None of the remaining genes in female zebrafish had their mRNA ex-
pression levels decreased, however cyp51 expression was notably down regulated by 1.2 
fold for 64 ng/L, even though it was not significant. Males, on the other hand, exhibited a 
1.7 fold significant down regulation when exposed to the same concentration. Male 
zebrafish also showed significant differences for srebp2 mRNA expression levels, with a 
down regulation of 1.48 fold in the higher concentration, 1600 ng/L. Neither males nor fe-
males presented significant alterations in dhcr7 mRNA expression. 
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Figure 16. Females’ relative mRNA expression of srebp2, hmgcra, cyp51, and dhcr7 in 
adult D. rerio livers after 90 days SIM exposure. Error bars indicate standard errors. Bars 
with different letters are significantly different from the solvent control treatment (ACET) 
(p<0.05). 
 
 
 
Figure 17. Males’ relative mRNA expression of srebp2, hmgcra, cyp51, and dhcr7 in adult 
D. rerio livers after 90 days SIM exposure. Error bars indicate standard errors. Bars with 
different letters are significantly different from the solvent control treatment (ACET) 
(p<0.05). 
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3.3. Cholesterol and Triglycerides quantification 
Cholesterol (Chol) quantification revealed that, after 90 days of exposure, SIM sig-
nificantly decreased its liver concentrations in female zebrafish at intermediate concentra-
tions, i.e. 64 ng/L and 320 ng/L with 53.56 and 64.59% decrease from control, respective-
ly (Figure 18). Males also exhibited the same pattern, however it did not shown significant 
differences from control treatments. Both males and females exhibited a slight increase in 
the highest concentration when compared with intermediate SIM exposed treatments, yet 
lower than controls. This biochemical marker developed a NMDRC in a similar way as 
mRNA transcript levels of hmgcra and cyp51 genes. 
Triglycerides (TGL) levels in female liver were significantly lower in all SIM concen-
trations, with the exception of 320 ng/L (Figure 19). Exposure to 12.8, 64, and 1600 ng/L 
of SIM was able to decrease TGL levels by 32.59, 26.57 and 45.89 %, respectively. No 
significant differences were observed in males.  
 
Figure 18. Chronic toxicity effects of SIM on D. rerio liver cholesterol content, expressed 
as µg per mg of extracted tissue, after 90 days of exposure. Error bars indicate standard 
errors; asterisks (*) indicate significant differences from the control group (p<0.05). As no 
significant differences were found between control and solvent control groups, the data 
from these two treatments were pooled and referred to as control.  
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Figure 19. Chronic toxicity effects of SIM on D. rerio liver triglycerides content, expressed 
as µg per mg of extracted tissue, after 90 days of exposure. Error bars indicate standard 
errors; asterisks (*) indicate significant differences from the control group (p<0.05). As no 
significant differences were found between control and solvent control groups, the data 
from these two treatments were pooled and referred to as control. 
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CHAPTER IV. 
Discussion 
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4. Discussion 
Hypocholesterolaemic drugs, such as SIM, are designed to produce, in humans, 
specific biological effects at low concentrations and therefore, once in the aquatic envi-
ronment, many aquatic taxa might be at risk. Despite the growing number of studies re-
garding acute toxicity of SIM in aquatic ecosystems, the chronic effects of this contami-
nant has not yet been properly studied although aquatic organisms are exposed for their 
entire life to chronic low levels (Santos et al., 2016).  
In order to address the current gap of knowledge regarding the effects of chronic 
exposure of non-target organisms to SIM, the present study aimed at investigating a multi-
level biological response in the model organism D. rerio, following a chronic exposure (90 
days) to environmentally relevant concentrations of SIM. This work integrated key ecolog-
ically relevant endpoints such as survival, growth, reproduction and embryonic develop-
ment and link it with SIM mode of action, focusing in cholesterol and triglycerides content 
and in the expression of key mevalonate pathway genes. Our results show that chronic 
SIM exposure induced several disruptive effects at biochemical/molecular levels and in 
early life stages of D. rerio, as well as at some ecologically relevant endpoints. Results 
also show some sex-dependent differences, suggesting that females and males may re-
spond differently to SIM. 
The chronic exposure to SIM in the ng/L range leads to a significant decrease of 
male weight at the highest exposed concentration (1600 ng/L). Some authors have re-
ported that weight loss is frequently accompanied with decreased cholesterol levels (Cong 
et al., 2012; Nam et al., 2014). However our study showed that the cholesterol levels of 
exposed males did not fall as expected. In contrast, the cholesterol levels of exposed fe-
male decreased but their body weight remain unaltered. Similar reduction of body weight 
were reported by Mu et al. (2015) in adult zebrafish exposed to difenoconazole. Thus, the 
body weight decrease observed here does not seem to be related with cholesterol levels, 
but may be linked with the effect of SIM on other parameters. However, the origin of body 
weight decrease in males after SIM exposure, should be better studied. Additionally, sig-
nificant differences were also observed for females’ fecundity. An increase in the number 
of embryos per female was reported for the highest SIM concentration (1600 ng/L) after 
70 days of exposure to SIM. This response may be due to compensatory mechanisms 
developed during the exposure period as an attempt to counterbalance the effects of SIM. 
The exposure to SIM could lead the animals to redirect their energy resources to maintain 
certain body functions in order to cope with the environmental alterations in a phenome-
non called allostasis: “the ability to achieve stability through change”. Even though this 
process demands high energy costs, it is able to increase the overall fitness of the animal 
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(Schreck, 2010), which could possibly be the reason for the improvement of zebrafish fe-
cundity.  To further address the effect of SIM in the reproduction, an embryo bioassay was 
performed with embryos resulting from the parental exposed generation and maintained in 
clean dechlorinated water. Our results showed an increase of embryo abnormalities for 
median and lowest SIM concentrations (12.8 and 64 ng/L) with tail abnormalities (curl 
and/or shortening of the tail) and developmental arrest being the most frequent anomalies. 
We also observed a significant increase in heart beats for 64 ng/L of SIM. Previous stud-
ies demonstrated that SIM exposure was able to produce similar morphologic alterations 
to those here observed. For instance, Cunha et al. (2016) observed embryos development 
arrest as well as curled tails, while tail shortening was observed by Campos et al. (2016). 
There was evidence that zebrafish embryos directly exposed to SIM also present abnor-
malities in the circulatory system such as pericardial edema (Campos et al., 2016; Cunha 
et al., 2016). The present study did not record all the detrimental effects reported in the 
literature.  In our experiment, embryos were exposed to SIM only during roughly two 
hours, meaning that parental exposure might be responsible for a significant amount of 
embryonic abnormalities. Several detrimental effects were here observed in the embryo 
bioassay, revealing that harmful effects produced by SIM exposure may possibly be 
passed to the second generation. Consequently, population level effects might occur, 
since the observed abnormalities in zebrafish embryos will, most likely affect the fitness of 
these animals and, consequently their survival. Although the detrimental effects observed 
at embryonic stages, SIM did not significantly impact Zebrafish key ecological endpoints 
such as growth and reproduction. It may be hypothesized that a longer exposure time, in-
volving whole life-cycle or multigenerational exposure, at the same environmental relevant 
SIM concentrations would be necessary to produce effects at other relevant ecologically 
relevant endpoints. Moreover, taking into account the effects obtained at molecular and 
biochemical levels, we expect more effects at ecological levels after longer exposures. 
Multigenerational assays could also be important to better understand the actual impact of 
the malformations obtained at embryonic development level.  
Cholesterol, as the precursor of steroid sex hormones, plays an important role in 
many essential biological processes, including reproduction (van der Wulp et al., 2013). 
Additionally, cholesterol has a particularly important role in the membrane as it helps regu-
late its fluidity and maintains the cell’s integrity (van der Wulp et al., 2013). On the other 
hand, in most animals, triglycerides play an important role in energy storage, being the 
main source of reliable energy used for growth, reproduction and maintenance of the or-
ganisms’ biological functions (Vergauwen et al., 2010). Due to its extreme importance, 
studying the cholesterol and triglycerides content of zebra fish exposed to SIM becomes 
essential in order to better understand this drug’s effect. In fact, our data revealed that 
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SIM was able to significantly reduce the cholesterol levels in females exposed to 64 and 
320 ng/L of SIM. These low levels of cholesterol observed in females exposed to SIM 
might be the reason for the abnormalities observed in the embryo bioassay. Our results 
suggest that cholesterol decrease in the parental generation can be associated with mor-
phologic abnormalities on the progeny and potential adverse effects at population level.  
Triglycerides quantification revealed similar behaviour as cholesterol, female zebrafish 
levels were significantly decreased in several SIM treatments (12.8; 64 and 1600 ng/L), 
with the highest concentration, i.e. 1600 ng/L, showing the lower levels. Male zebrafish did 
not shown any significant differences in triglyceride and cholesterol content but presented 
slight decrease with the increase of SIM concentrations. It is possible that the decrease of 
triglycerides and cholesterol reserves in females zebrafish are due to the expenses need-
ed for reproduction, which generally produce high amounts of eggs in a regular basis con-
taining large amounts of lipid reserves (Landgraf et al., 2017). Similar effects on choles-
terol and triglycerides levels were already reported by Al-Habsi et al. (2016) after exposing 
zebrafish to atorvastatin for 30 days. A significant reduction of cholesterol and triglycer-
ides were observed by Al-Habsi et al. (2016) only for females. Interestingly, in the current 
study, the treatments in which triglycerides decreased (12.8, 64 and 1600 ng/L of SIM) 
were the same in which the female fecundity increased. It is possible that triglycerides 
were used as energy source for the previously discussed adaptation mechanisms devel-
oped for maintenance of zebrafish reproduction. Sex dependent effects were observed in 
some of the analysed endpoints on both biochemical and molecular levels. Females 
seemed to be more prone to biochemical changes, while at molecular level males showed 
more changes in gene expression. 
Cholesterol reduction through the inhibition of the conversion of HMG-CoA to 
mevalonate by the enzyme HMGCR have been exhaustively studied in humans and other 
mammalian organisms for more than fifty years since its discovery by Siperstein and 
Guest (1960). Several studies have demonstrated that HMGCR inhibition by statins led to 
a decline in MVA synthesis and its downstream products leading to the inhibition of cho-
lesterol biosynthesis. A negative feedback regulation takes place, carried out by SREBP2 
activation, which promotes the transcription of HMGCR and LDL receptor, which play an 
important role in cholesterol synthesis and uptake, respectively (Figure 3). As this path-
way is highly conserved through vertebrates, we expect the same mechanisms of action 
of statins (SIM) occurring in aquatic vertebrates, such as zebrafish (Santos, et al., 2016). 
Some previous studies with statins in aquatic vertebrates have obtained low levels of cho-
lesterol, as well as the presence of the feedback mechanism regulation at transcriptional 
levels by presenting increased levels of mRNA expression of genes such as srebp2, 
hmgcr and ldlr in a similar way as in mammals.  
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In order to obtain a more complete analysis of long-term effects of SIM in 
zebrafish, we also integrated in this study a molecular assessment of several genes ex-
pression involved in the mevalonate pathway. Taking into account the literature, we hy-
pothesised that mRNA expression of both hmgcra and srebp2 would increase. In contrast, 
our results showed that mRNA expression of SREBP2 for males and females maintained 
its levels near control group or significantly decrease in several SIM concentration for both 
males and females.  As a consequence of the lack of increase of the mRNA expression of 
srebp2, we observed that mRNA content in hmgcra significantly decreased for both males 
and females exposed to 64 and 320 ng/L of SIM. There is no apparent explanation in the 
literature for this response. Since SREBP2 plays a major role in the feedback regulation of 
cholesterol which end up increase cholesterol synthesis once their levels have lowered 
after statin treatment, some authors have discussed possible ways of inhibiting the activity 
of SREBP2 as a way of lowering cholesterol levels more efficiently.  In fact, to the best of 
our knowledge no studies in the literature have shown the down regulation of srebp2 and 
hmgcra after statin treatment, most of the studies available report up regulation of these 
genes when cholesterol levels decreased due to the natural feedback mechanism of the 
MVA pathway. Most studies regarding SIM MOA in vertebrates which obtained these re-
sults are based on short acute exposures. However it is possible that chronic exposures 
might result in different effects (Al-Habsi et al., 2016; Egom & Hafeez, 2016; Xiao & Song, 
2013). However it is also possible that the observed effect could be a result of fluctuations 
in gene expression or feedback mechanism at the time-point the sampling was performed. 
More research should be performed in order to better assess long-term effects of SIM in 
srebp2 and clarify as well if there is another pathway that might be involved on its regula-
tion.  
 As a consequence of hmgcra down regulation, it is likely that genes downstream 
in the pathway most likely should be down regulated as well, which was observed for 
cyp51. For being the key factor in the hydrogenation of 7-dehydrocholesterol, the precur-
sor of cholesterol (Figure 3), dhcr7 expression was also assessed. However, even though 
cholesterol levels suffered a significant decrease, dhcr7 mRNA transcript levels remained 
unaltered. There is a clear lack of knowledge necessary to explain the gene expression 
profile observed after long-term exposure to SIM. Therefore, expression of additional 
genes related to cholesterol biosynthetic pathway should be assessed. Genes related to 
transport, efflux and degradation of both SIM and cholesterol should also be quantified 
since these are some of the mechanisms that may also influence cholesterol levels, as 
well as SIM accumulation in the organism.  
Our results on the mRNA transcript levels of srebp2 and hmgcra seem to be dif-
ferent to data recorded in the literature. However there are also some studies revealing 
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contrasting results around statins ability to decrease cholesterol synthesis as well. For in-
stance, Goldberg et al. (1990) found out that patients used lovastatin to treat high choles-
terol levels were not able to reduce cholesterol synthesis. Kallen et al. (1999) even re-
vealed to have observed increased cholesterol synthesis when treating his patients with 
pravastatin. Raghow (2017) stated that although a high amount of research has been 
done over the last decades in cultured cells and experimental animals, the mechanistic 
details underling statins effects in vitro are still poorly understood, revealing urgent neces-
sity of in vivo testing of these pharmaceuticals. 
Some of our most relevant results showed a non-monotonic dose response curve 
(NMDRC) with a U-shaped curve (for cholesterol quantification and gene expression) and 
inverted U-shaped (for embryonic abnormalities). A NMDRC is mathematically defined as 
a response where the slope of the curve changes sign from positive to negative, or vice-
versa in the range of doses examined (Kohn & Melnick, 2002). The mechanisms that 
cause this non-monotonicity are currently unknown. For many years, it was assumed that 
contaminants exhibited linear monotonic responses, assuming that “the dose makes the 
poison” (Vandenberg et al., 2012). However in the last years the occurrence of NMDRC 
has been more frequently documented (Andrade et al., 2006; Barros et al., 2017; 
Crépeaux et al., 2016; Do et al., 2012; Faigón et al., 2014; Kim et al., 2014). Calabrese 
and Baldwin (2016) stated that NMDRCs might occur more frequently than it is expected. 
The reason behind this is that NMDRCs based in adaptation mechanisms are generally 
dependent of exposure time and range of concentrations tested. It was already known that 
these kind of response curves generally occur at low-level concentration. However, time 
of exposure can also greatly influence their occurrence, because adaptation mechanisms 
need time to develop and it is difficult to predict the time during which the response will 
occur and/or be maintained, meaning that in the majority of studies performed exposure 
time may be too brief or too long in order to detect this type of NMDRC.  There are no 
records of this type of response for SIM or other statins until the present study. The rea-
son behind it might be that in most cases, studies with statins had shorter exposure peri-
ods, as well as higher concentrations when compared to the conditions of our experiment. 
It is also possible that the non-monotonic curves obtained in this study may be a result of 
the development of an adaptive response to overcompensate the effects of SIM at the 
highest SIM concentrations tested. Muskak (2016) argued that adaptation mechanisms 
may produce NMDRCs after exposure to certain contaminants and that this kind of re-
sponse may be transitory or continue to operate during long periods of time upon low-level 
chronic exposures. 
Our experiment revealed several interesting and new results not yet reported in 
the literature for this class of pharmaceuticals. It is highly necessary to perform more stud-
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ies in both aquatic vertebrates and invertebrates in order to clarify the mode of action be-
hind SIM long term exposures, which might be more relevant than expected. 
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Conclusion 
 
 Our study revealed that SIM was able to affect the MVA pathway in the aquatic 
vertebrate D. rerio. Despite SIM significantly affected the majority of our tested endpoints, 
i.e. ecological, biochemical and molecular endpoints, many questions remain about the 
mode of action of statins after long-term exposures. Our study reported for the first time, 
several non-monotonic dose-response curves for statin exposure at biochemical and mo-
lecular endpoints. Results on the embryonic assay raised great concern regarding the fu-
ture of aquatic vertebrate’ populations. The environmental realistic concentrations as-
sessed in our study revealed several abnormalities in the embryos of animals which had 
their cholesterol levels significantly decreased. It is also important to note that in this ex-
periment was based in a partial life-cycle exposure with a duration of 90 days. Therefore, 
a multigenerational exposure to SIM should be performed in order to simulate a more real-
istic scenario of environmental exposure to SIM and better understand the potential ef-
fects at individual and population levels, as well as provide additional insights in the un-
derstanding of the responses obtained in the present study and their implications. 
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